Exploring Emerging Data in DLBCL
A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Looking at the Big Picture in DLBCL
Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.
Treating Patients Post CAR T Therapy
David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
Optimal Approaches to Bridging Therapy in DLBCL
Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.
Evaluating CAR T Therapies in Lymphoma
A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.
Recommendations for CAR T-Cell Therapy in R/R DLBCL
Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.
Newer Approvals for Previously Treated DLBCL
A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.
DLBCL: Approaches to Treating Patients Ineligible for Transplant
Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.
Data From the L-MIND Trial
Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).
Recommendations for Second-Line Therapy in DLBCL
Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.
Managing Relapsed DLBCL
Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.
Outlook for CNS Lymphoma
David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.
DLBCL: Approaching CNS Prophylaxis
A panel of experts explain how they approach CNS prophylaxis in DLBCL.
Treatment Considerations in DLBCL
Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.
Treating Newly Diagnosed Patients With DLBCL
Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
2 Clarke Drive Cranbury, NJ 08512